首页 > 最新文献

Journal of travel medicine最新文献

英文 中文
Hepatitis a vaccine immunogenicity and boostability in adults receiving immunosuppressive therapy and adults living with HIV: a prospective single-Centre cohort study. 接受免疫抑制治疗的成人和感染艾滋病毒的成人接种甲型肝炎疫苗的免疫原性和增强性:一项前瞻性单中心队列研究。
IF 25.7 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-09-11 DOI: 10.1093/jtm/taae125
Jenny L Schnyder,Hannah M Garcia Garrido,Michael W Tanck,Irma Maurer,Agnes M Harskamp,Neeltje Kootstra,Martin P Grobusch,Abraham Goorhuis
INTRODUCTIONHepatitis A (hepA) vaccination is highly immunogenic in healthy individuals, however there is uncertainty about the immunogenicity in immunocompromised populations (ICPs).METHODSIn this prospective cohort study, people living with HIV (PLWH), patients on immunosuppressive mono- and combination therapy, and controls received two hepA vaccine doses at months 0 and 6-12, or three combined hepA/B vaccine doses at months 0, 1 and 6-12. Antibody levels were measured before and at different time-points post-vaccination (T2, 6, 8, 12 months). The primary endpoint was the seroconversion rate (SCR) at T8, defined as hepA antibodies ≥20 mIU/ml. To assess boostability, an additional vaccine dose was administered 1-5 years after T12 in those with antibodies < 50 mIU/ml, with antibody measurements before and seven days after the booster dose.RESULTSWe included 150 participants. At T2 SCRs ranged between 35-58% in ICPs versus 94% in controls. Among PLWH, patients on monotherapy, combination therapy and controls SCRs at T8 were 33/34 (97%), 32/34 (94%), 25/30 (83%) and 28/28 (100%) respectively. The booster dose resulted in 71% additional seroconversion (17/24), with only patients using combination therapy not responding.CONCLUSIONSHepA vaccination is highly immunogenic in virologically suppressed PLWH and patients on immunosuppressive monotherapy, with SCRs after the complete hepA vaccination schedule similar to controls and adequate booster responses in case of waning immunity. However, patients using immunosuppressive combination therapy as well as all ICPs who did not receive the complete hepA vaccination schedule, are at risk of non-response to vaccination and post-vaccination antibody measurements are recommended.
在这项前瞻性队列研究中,艾滋病病毒感染者(PLWH)、接受免疫抑制单一疗法和联合疗法的患者以及对照组分别在第 0 个月和第 6-12 个月接种了两剂甲肝疫苗,或在第 0 个月、第 1 个月和第 6-12 个月接种了三剂甲肝/乙肝联合疫苗。在接种前和接种后的不同时间点(T2、6、8、12 个月)测量抗体水平。主要终点是T8时的血清转换率(SCR),定义为hepA抗体≥20 mIU/ml。为了评估增强性,在抗体<50 mIU/ml的人群中,在T12后1-5年再接种一剂疫苗,并在接种前和接种后7天测量抗体。在 T2 阶段,ICP 的 SCR 为 35% 至 58%,而对照组的 SCR 为 94%。在 PLWH 中,接受单一疗法、联合疗法和对照疗法的患者在 T8 的 SCR 分别为 33/34 (97%)、32/34 (94%)、25/30 (83%) 和 28/28 (100%)。结论在病毒学抑制的 PLWH 和接受免疫抑制单药治疗的患者中,接种 HepA 疫苗具有很高的免疫原性,完整的 HepA 疫苗接种程序后的 SCR 与对照组相似,并且在免疫力下降时有足够的加强应答。但是,使用免疫抑制剂联合疗法的患者以及所有未按计划接种完整乙肝疫苗的 ICPs 都有可能对疫苗接种无反应,因此建议进行接种后抗体测定。
{"title":"Hepatitis a vaccine immunogenicity and boostability in adults receiving immunosuppressive therapy and adults living with HIV: a prospective single-Centre cohort study.","authors":"Jenny L Schnyder,Hannah M Garcia Garrido,Michael W Tanck,Irma Maurer,Agnes M Harskamp,Neeltje Kootstra,Martin P Grobusch,Abraham Goorhuis","doi":"10.1093/jtm/taae125","DOIUrl":"https://doi.org/10.1093/jtm/taae125","url":null,"abstract":"INTRODUCTIONHepatitis A (hepA) vaccination is highly immunogenic in healthy individuals, however there is uncertainty about the immunogenicity in immunocompromised populations (ICPs).METHODSIn this prospective cohort study, people living with HIV (PLWH), patients on immunosuppressive mono- and combination therapy, and controls received two hepA vaccine doses at months 0 and 6-12, or three combined hepA/B vaccine doses at months 0, 1 and 6-12. Antibody levels were measured before and at different time-points post-vaccination (T2, 6, 8, 12 months). The primary endpoint was the seroconversion rate (SCR) at T8, defined as hepA antibodies ≥20 mIU/ml. To assess boostability, an additional vaccine dose was administered 1-5 years after T12 in those with antibodies < 50 mIU/ml, with antibody measurements before and seven days after the booster dose.RESULTSWe included 150 participants. At T2 SCRs ranged between 35-58% in ICPs versus 94% in controls. Among PLWH, patients on monotherapy, combination therapy and controls SCRs at T8 were 33/34 (97%), 32/34 (94%), 25/30 (83%) and 28/28 (100%) respectively. The booster dose resulted in 71% additional seroconversion (17/24), with only patients using combination therapy not responding.CONCLUSIONSHepA vaccination is highly immunogenic in virologically suppressed PLWH and patients on immunosuppressive monotherapy, with SCRs after the complete hepA vaccination schedule similar to controls and adequate booster responses in case of waning immunity. However, patients using immunosuppressive combination therapy as well as all ICPs who did not receive the complete hepA vaccination schedule, are at risk of non-response to vaccination and post-vaccination antibody measurements are recommended.","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":"7 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142186978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine 从实验室到临床:开发基孔肯雅减毒活疫苗 VLA1553/IXCHIQ
IF 25.7 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-09-09 DOI: 10.1093/jtm/taae123
Lin H Chen, Andrea Fritzer, Romana Hochreiter, Katrin Dubischar, Stéphanie Meyer
Background Over the past 20 years, over 5 million cases of chikungunya, a mosquito-transmitted viral disease, have been reported in over 110 countries. Until recently, preventative strategies for chikungunya were largely ineffective, relying on vector control and individual avoidance of mosquito bites. Methods This review outlines the preclinical and clinical efficacy and safety data that led to the approval of VLA1553 (IXCHIQ®), a live-attenuated vaccine against chikungunya disease. It also describes the innovative development pathway of VLA1553, based on an immunological surrogate of protection, and discusses ongoing and future post-licensure studies. Results In mice and non-human primate models, VLA1553 elicited high titres of neutralizing antibodies, conferred protection against wild-type chikungunya virus challenge and raised no safety concerns. A Phase 1 clinical trial of VLA1553 demonstrated 100% seroconversion among 120 healthy participants, with sustained neutralizing antibody titres after 12 months. These results and determination of a surrogate marker of protection led to advancement of VLA1553 directly into Phase 3 clinical development, as agreed with the US Food and Drug Administration (FDA) and the European Medicines Agency. The pivotal Phase 3 trial met its primary immunogenicity endpoint, achieving seroprotective levels based on immuno-bridging in baseline seronegative participants 28 days post-vaccination. These findings enabled submission of a Biologics License Application to the FDA for accelerated approval of VLA1553 in the US for adults aged ≥18 years. Ongoing and planned studies will confirm the clinical efficacy/effectiveness and safety of VLA1553 in adults and younger individuals, and will generate data in chikungunya endemic countries that have the highest unmet need. Conclusion VLA1553 is the first vaccine approved for the prevention of chikungunya disease in adults, following accelerated development based on a serological surrogate marker of protection. VLA1553 adds to strategies to reduce the spread and burden of chikungunya in endemic populations and travellers.
背景 在过去 20 年里,110 多个国家报告了 500 多万例基孔肯雅病病例,这是一种由蚊子传播的病毒性疾病。直到最近,基孔肯雅病的预防策略仍主要依靠病媒控制和个人避免蚊虫叮咬,效果不佳。方法 本综述概述了导致基孔肯雅病减毒活疫苗 VLA1553 (IXCHIQ®) 获得批准的临床前和临床有效性与安全性数据。报告还介绍了基于免疫学保护替代物的 VLA1553 创新开发途径,并讨论了正在进行的和未来的许可后研究。结果 在小鼠和非人灵长类动物模型中,VLA1553 可激发高滴度的中和抗体,对野生型基孔肯雅病毒挑战具有保护作用,并且不存在安全性问题。VLA1553 的 1 期临床试验表明,120 名健康参与者的血清转换率达到 100%,12 个月后中和抗体滴度仍能保持稳定。这些结果和替代保护标志物的确定促使 VLA1553 直接进入 3 期临床开发,这也是与美国食品药品管理局 (FDA) 和欧洲药品管理局达成的协议。关键的 3 期临床试验达到了主要的免疫原性终点,在接种疫苗后 28 天,根据免疫桥接,基线血清阴性参与者达到了血清保护水平。这些研究结果有助于向美国食品药品管理局提交生物制品许可申请,加速批准 VLA1553 在美国用于年龄≥18 岁的成人。正在进行和计划进行的研究将确认 VLA1553 在成人和年轻人中的临床疗效/有效性和安全性,并将在基孔肯雅病流行国家获得数据,这些国家的需求尚未得到最大程度的满足。结论 VLA1553 是基于血清学替代保护标志物加速开发后批准用于预防成人基孔肯雅病的首个疫苗。VLA1553 为减少基孔肯雅病在流行人群和旅行者中的传播和负担的战略增添了新的内容。
{"title":"From bench to clinic: the development of VLA1553/IXCHIQ, a live-attenuated chikungunya vaccine","authors":"Lin H Chen, Andrea Fritzer, Romana Hochreiter, Katrin Dubischar, Stéphanie Meyer","doi":"10.1093/jtm/taae123","DOIUrl":"https://doi.org/10.1093/jtm/taae123","url":null,"abstract":"Background Over the past 20 years, over 5 million cases of chikungunya, a mosquito-transmitted viral disease, have been reported in over 110 countries. Until recently, preventative strategies for chikungunya were largely ineffective, relying on vector control and individual avoidance of mosquito bites. Methods This review outlines the preclinical and clinical efficacy and safety data that led to the approval of VLA1553 (IXCHIQ®), a live-attenuated vaccine against chikungunya disease. It also describes the innovative development pathway of VLA1553, based on an immunological surrogate of protection, and discusses ongoing and future post-licensure studies. Results In mice and non-human primate models, VLA1553 elicited high titres of neutralizing antibodies, conferred protection against wild-type chikungunya virus challenge and raised no safety concerns. A Phase 1 clinical trial of VLA1553 demonstrated 100% seroconversion among 120 healthy participants, with sustained neutralizing antibody titres after 12 months. These results and determination of a surrogate marker of protection led to advancement of VLA1553 directly into Phase 3 clinical development, as agreed with the US Food and Drug Administration (FDA) and the European Medicines Agency. The pivotal Phase 3 trial met its primary immunogenicity endpoint, achieving seroprotective levels based on immuno-bridging in baseline seronegative participants 28 days post-vaccination. These findings enabled submission of a Biologics License Application to the FDA for accelerated approval of VLA1553 in the US for adults aged ≥18 years. Ongoing and planned studies will confirm the clinical efficacy/effectiveness and safety of VLA1553 in adults and younger individuals, and will generate data in chikungunya endemic countries that have the highest unmet need. Conclusion VLA1553 is the first vaccine approved for the prevention of chikungunya disease in adults, following accelerated development based on a serological surrogate marker of protection. VLA1553 adds to strategies to reduce the spread and burden of chikungunya in endemic populations and travellers.","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":"31 1","pages":""},"PeriodicalIF":25.7,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142186979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Imported malaria in China. 中国的输入性疟疾。
IF 9.1 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-09-04 DOI: 10.1093/jtm/taae124
Thomas Zoller
{"title":"Imported malaria in China.","authors":"Thomas Zoller","doi":"10.1093/jtm/taae124","DOIUrl":"https://doi.org/10.1093/jtm/taae124","url":null,"abstract":"","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142133081","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sacred journeys and pilgrimages: health risks associated with travels for religious purposes. 神圣之旅和朝圣:与宗教旅行有关的健康风险。
IF 9.1 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-08-31 DOI: 10.1093/jtm/taae122
Salim Parker, Robert Steffen, Harunor Rashid, Miguel M Cabada, Ziad A Memish, Philippe Gautret, Cheikh Sokhna, Avinash Sharma, David R Shlim, Eyal Leshem, Dominic E Dwyer, Faris Lami, Santanu Chatterjee, Shuja Shafi, Alimuddin Zumla, Ozayr Mahomed

Background: Pilgrimages and travel to religious Mass Gatherings (MGs) are part of all major religions. This narrative review aims to describe some characteristics, including health risks, of the more well known and frequently undertaken ones.

Methods: A literature search was conducted using keywords related to the characteristics (frequency of occurrence, duration, calendar period, reasons behind their undertaking and the common health risks) of Christian, Muslim, Hindu, Buddhist and Jewish religious MGs.

Results: About 600 million trips are undertaken to religious sites annually. The characteristics varies between religions and between pilgrimages. However, religious MGs share common health risks, but these are reported in a heterogenous manner. European Christian pilgrimages reported both communicable diseases, such as norovirus outbreaks linked to the Marian Shrine of Lourdes in France, and noncommunicable diseases (NCD). NCD predominated at the Catholic pilgrimage to the Basilica of Our Lady of Guadalupe in Mexico, which documented 11 million attendees in one week. The Zion Christian Church Easter gathering in South Africa, attended by about 10 million pilgrims, reported mostly motor vehicles accidents. Muslim pilgrimages, such as the Arbaeen (20 million pilgrims) and Hajj documented a high incidence of respiratory tract infections, up to 80% during Hajj. Heat injuries and stampedes have been associated with Hajj. The Hindu Kumbh Mela pilgrimage, which attracted 100 million pilgrims in 2013, documented respiratory conditions in 70% of consultations. A deadly stampede occurred at the 2021 Jewish Lag BaOmer MG.

Conclusion: Communicable and NCD differ among the different religious MGs. Gaps exists in the surveillance, reporting, and data accessibility of health risks associated with religious MGs. A need exists for the uniform implementation of a system of real-time monitoring of diseases and morbidity patterns, utilising standardised modern information-sharing platforms. The health needs of pilgrims can then be prioritised by developing specific and appropriate guidelines.

背景:朝圣和参加宗教弥撒(MGs)是所有主要宗教的一部分。这篇叙述性综述旨在描述一些众所周知且经常举行的弥撒的特点,包括健康风险:方法:使用与基督教、穆斯林、印度教、佛教和犹太教宗教集会的特点(发生频率、持续时间、日历期间、举行集会的原因以及常见的健康风险)相关的关键词进行文献检索:结果:每年约有 6 亿人次前往宗教场所。不同宗教和不同朝圣地的特点各不相同。然而,宗教朝圣活动具有共同的健康风险,但报告的方式却不尽相同。欧洲基督教朝圣活动既报告了传染病,如与法国卢尔德圣母圣殿有关的诺如病毒爆发,也报告了非传染性疾病(NCD)。非传染性疾病在墨西哥瓜达卢佩圣母大教堂天主教朝圣活动中占主导地位,据记录,一周内有 1,100 万人参加了朝圣活动。南非锡安基督教会的复活节聚会约有 1 000 万名朝圣者参加,报告的事故主要是机动车事故。穆斯林朝圣,如阿尔巴恩朝圣(2000 万朝圣者)和朝觐,呼吸道感染的发病率很高,朝觐期间高达 80%。热伤害和踩踏事件也与朝觐有关。2013 年,印度教 Kumbh Mela 朝圣活动吸引了 1 亿朝圣者,据记录,70% 的就诊者患有呼吸道疾病。在 2021 年的犹太教 Lag BaOmer MG 上发生了致命的踩踏事件:传染病和非传染性疾病在不同宗教的旅游景点有所不同。与宗教活动相关的健康风险在监测、报告和数据获取方面存在差距。有必要利用标准化的现代信息共享平台,统一实施疾病和发病模式实时监测系统。然后,可以通过制定具体和适当的指导方针,优先考虑朝圣者的健康需求。
{"title":"Sacred journeys and pilgrimages: health risks associated with travels for religious purposes.","authors":"Salim Parker, Robert Steffen, Harunor Rashid, Miguel M Cabada, Ziad A Memish, Philippe Gautret, Cheikh Sokhna, Avinash Sharma, David R Shlim, Eyal Leshem, Dominic E Dwyer, Faris Lami, Santanu Chatterjee, Shuja Shafi, Alimuddin Zumla, Ozayr Mahomed","doi":"10.1093/jtm/taae122","DOIUrl":"https://doi.org/10.1093/jtm/taae122","url":null,"abstract":"<p><strong>Background: </strong>Pilgrimages and travel to religious Mass Gatherings (MGs) are part of all major religions. This narrative review aims to describe some characteristics, including health risks, of the more well known and frequently undertaken ones.</p><p><strong>Methods: </strong>A literature search was conducted using keywords related to the characteristics (frequency of occurrence, duration, calendar period, reasons behind their undertaking and the common health risks) of Christian, Muslim, Hindu, Buddhist and Jewish religious MGs.</p><p><strong>Results: </strong>About 600 million trips are undertaken to religious sites annually. The characteristics varies between religions and between pilgrimages. However, religious MGs share common health risks, but these are reported in a heterogenous manner. European Christian pilgrimages reported both communicable diseases, such as norovirus outbreaks linked to the Marian Shrine of Lourdes in France, and noncommunicable diseases (NCD). NCD predominated at the Catholic pilgrimage to the Basilica of Our Lady of Guadalupe in Mexico, which documented 11 million attendees in one week. The Zion Christian Church Easter gathering in South Africa, attended by about 10 million pilgrims, reported mostly motor vehicles accidents. Muslim pilgrimages, such as the Arbaeen (20 million pilgrims) and Hajj documented a high incidence of respiratory tract infections, up to 80% during Hajj. Heat injuries and stampedes have been associated with Hajj. The Hindu Kumbh Mela pilgrimage, which attracted 100 million pilgrims in 2013, documented respiratory conditions in 70% of consultations. A deadly stampede occurred at the 2021 Jewish Lag BaOmer MG.</p><p><strong>Conclusion: </strong>Communicable and NCD differ among the different religious MGs. Gaps exists in the surveillance, reporting, and data accessibility of health risks associated with religious MGs. A need exists for the uniform implementation of a system of real-time monitoring of diseases and morbidity patterns, utilising standardised modern information-sharing platforms. The health needs of pilgrims can then be prioritised by developing specific and appropriate guidelines.</p>","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fatal journeys: causes of death in international travellers in South America. 致命旅程:南美洲国际旅行者的死亡原因。
IF 9.1 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-08-29 DOI: 10.1093/jtm/taae119
Kasim Allel, Miguel M Cabada, Behzad Kiani, Beatris Mario Martin, Melinda Tanabe, Angela Cadavid Restrepo, Gabriela De Souza Dos Santos, Susana Lloveras, Wondimeneh Shiferaw, Benn Sartorius, Deborah J Mills, Colleen L Lau, Luis Furuya-Kanamori

Background: Understanding mortality among travellers is essential for mitigating risks and enhancing travel safety. However, limited evidence exists on severe illnesses and injuries leading to death among travellers, particularly in low- and middle-income countries and remote regions.

Methods: We conducted a retrospective census study using country-level observational data from death certificates of travellers of seven South American countries (Argentina, Brazil, Chile, Colombia, Ecuador, Peru, and Uruguay) from 2017 to 2021. Causes of death were evaluated using ICD-10 codes, categorised into non-communicable diseases (NCDs), communicable diseases, and injuries. We quantified causes of death by demographic characteristics (e.g. age, sex), and geographical variables. Chi-square tests were used to assess differences between categories. We calculated crude mortality rates and incidence rate ratios (IRRs) per country's subregions.

Results: A total of 17 245 deaths were reported. NCDs (55%) were the most common cause of death, followed by communicable diseases (23.4%) and injuries (18.1%). NCD-associated deaths increased after age 55 years and were highest among ≥85 years. Communicable diseases were more common at younger age (<20 years). Injury-associated deaths were more common in men (79.9%) and 25-29-year-olds (17.1%). Most deaths (68.2%) could have been avoided by prevention or treatment. Mortality risk was higher among travellers in bordering regions between countries. In Roraima [Brazil] and Norte de Santander [Colombia], locations bordering Venezuela, the death incidence rate ratio was 863 and 60, respectively. These countries' reference mortality rates in those regions were much lower. More than 80% of the deaths in these border regions of Brazil and Colombia involved Venezuelan citizens. Conclusion: The study identified risk factors and high-risk locations for deaths among travellers in seven countries of South America. Our findings underscore the need for specific health interventions tailored to traveller demographics and destination to optimise prevention of avoidable deaths in South America.

背景:了解旅行者的死亡率对于降低风险和提高旅行安全至关重要。然而,有关导致旅行者死亡的严重疾病和伤害的证据有限,尤其是在中低收入国家和偏远地区:我们利用 2017 年至 2021 年南美七国(阿根廷、巴西、智利、哥伦比亚、厄瓜多尔、秘鲁和乌拉圭)旅行者死亡证明书中的国家级观察数据开展了一项回顾性普查研究。死亡原因使用 ICD-10 编码进行评估,分为非传染性疾病 (NCD)、传染性疾病和伤害。我们按人口特征(如年龄、性别)和地理变量对死因进行了量化。我们使用卡方检验来评估不同类别之间的差异。我们计算了各国分地区的粗死亡率和发病率比:结果:共报告了 17 245 例死亡。非传染性疾病(55%)是最常见的死亡原因,其次是传染性疾病(23.4%)和伤害(18.1%)。与非传染性疾病相关的死亡人数在 55 岁以后有所增加,在≥85 岁的人群中最高。传染病在年轻人中更为常见 (
{"title":"Fatal journeys: causes of death in international travellers in South America.","authors":"Kasim Allel, Miguel M Cabada, Behzad Kiani, Beatris Mario Martin, Melinda Tanabe, Angela Cadavid Restrepo, Gabriela De Souza Dos Santos, Susana Lloveras, Wondimeneh Shiferaw, Benn Sartorius, Deborah J Mills, Colleen L Lau, Luis Furuya-Kanamori","doi":"10.1093/jtm/taae119","DOIUrl":"https://doi.org/10.1093/jtm/taae119","url":null,"abstract":"<p><strong>Background: </strong>Understanding mortality among travellers is essential for mitigating risks and enhancing travel safety. However, limited evidence exists on severe illnesses and injuries leading to death among travellers, particularly in low- and middle-income countries and remote regions.</p><p><strong>Methods: </strong>We conducted a retrospective census study using country-level observational data from death certificates of travellers of seven South American countries (Argentina, Brazil, Chile, Colombia, Ecuador, Peru, and Uruguay) from 2017 to 2021. Causes of death were evaluated using ICD-10 codes, categorised into non-communicable diseases (NCDs), communicable diseases, and injuries. We quantified causes of death by demographic characteristics (e.g. age, sex), and geographical variables. Chi-square tests were used to assess differences between categories. We calculated crude mortality rates and incidence rate ratios (IRRs) per country's subregions.</p><p><strong>Results: </strong>A total of 17 245 deaths were reported. NCDs (55%) were the most common cause of death, followed by communicable diseases (23.4%) and injuries (18.1%). NCD-associated deaths increased after age 55 years and were highest among ≥85 years. Communicable diseases were more common at younger age (<20 years). Injury-associated deaths were more common in men (79.9%) and 25-29-year-olds (17.1%). Most deaths (68.2%) could have been avoided by prevention or treatment. Mortality risk was higher among travellers in bordering regions between countries. In Roraima [Brazil] and Norte de Santander [Colombia], locations bordering Venezuela, the death incidence rate ratio was 863 and 60, respectively. These countries' reference mortality rates in those regions were much lower. More than 80% of the deaths in these border regions of Brazil and Colombia involved Venezuelan citizens. Conclusion: The study identified risk factors and high-risk locations for deaths among travellers in seven countries of South America. Our findings underscore the need for specific health interventions tailored to traveller demographics and destination to optimise prevention of avoidable deaths in South America.</p>","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142108713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Kumbh Mela religious mass gathering in India: reducing risks for crowd-surge associated deaths and crush injuries. 印度 Kumbh Mela 大型宗教集会:降低与人群激增相关的死亡和挤压伤害风险。
IF 9.1 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-08-27 DOI: 10.1093/jtm/taae116
Avinash Sharma, Brian McCloskey, Salim Parker, Shuja Shafi, Esam I Azhar, Ziad A Memish, Alimuddin Zumla
{"title":"The Kumbh Mela religious mass gathering in India: reducing risks for crowd-surge associated deaths and crush injuries.","authors":"Avinash Sharma, Brian McCloskey, Salim Parker, Shuja Shafi, Esam I Azhar, Ziad A Memish, Alimuddin Zumla","doi":"10.1093/jtm/taae116","DOIUrl":"https://doi.org/10.1093/jtm/taae116","url":null,"abstract":"","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142080639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cognitive effects of altitude exposure. 高海拔对认知的影响
IF 9.1 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-08-22 DOI: 10.1093/jtm/taae112
Johannes Burtscher, Max Gassmann, Hannelore Ehrenreich, Katharina Hüfner, Martin Kopp, Martin Burtscher
{"title":"Cognitive effects of altitude exposure.","authors":"Johannes Burtscher, Max Gassmann, Hannelore Ehrenreich, Katharina Hüfner, Martin Kopp, Martin Burtscher","doi":"10.1093/jtm/taae112","DOIUrl":"https://doi.org/10.1093/jtm/taae112","url":null,"abstract":"","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142036181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Streamlining malaria prevention recommendations for travellers: current and future approaches. 简化针对旅行者的疟疾预防建议:当前和未来的方法。
IF 9.1 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-08-21 DOI: 10.1093/jtm/taae113
Sarah L McGuinness, Olivia Veit, Martin Angelin, Pietro Antonini, Gerhard Boecken, Margarita Boering, Silja Bühler, Guido Calleri, Gilles Éperon, Gerard Flaherty, Celine Gossner, Helena H Askling, Ville Holmberg, Esther Kuenzli, Pierre Landry, Eva Lefevre, Michael Libman, Nicky Longley, Ula Maniewski-Kelner, Andreas Neumayr, Christophe Rapp, Alison D Ridpath, Natalia Rodriguez, Anja Rosdahl, Deike Rosenbusch, Andrea Rossanese, Camilla Rothe, Patricia Schlagenhauf, Patrick Soentjens, Cornelia Staehelin, Jenny Visser, Leo Visser, Angelika Wagner, Allison Walker, Ursula Wiedermann, Agnieszka Wroczynska, Christoph Hatz
{"title":"Streamlining malaria prevention recommendations for travellers: current and future approaches.","authors":"Sarah L McGuinness, Olivia Veit, Martin Angelin, Pietro Antonini, Gerhard Boecken, Margarita Boering, Silja Bühler, Guido Calleri, Gilles Éperon, Gerard Flaherty, Celine Gossner, Helena H Askling, Ville Holmberg, Esther Kuenzli, Pierre Landry, Eva Lefevre, Michael Libman, Nicky Longley, Ula Maniewski-Kelner, Andreas Neumayr, Christophe Rapp, Alison D Ridpath, Natalia Rodriguez, Anja Rosdahl, Deike Rosenbusch, Andrea Rossanese, Camilla Rothe, Patricia Schlagenhauf, Patrick Soentjens, Cornelia Staehelin, Jenny Visser, Leo Visser, Angelika Wagner, Allison Walker, Ursula Wiedermann, Agnieszka Wroczynska, Christoph Hatz","doi":"10.1093/jtm/taae113","DOIUrl":"https://doi.org/10.1093/jtm/taae113","url":null,"abstract":"","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142017884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Entirely extracted Tunga penetrans in a traveller to Guinea-Bissau. 在几内亚比绍的一名旅行者体内完全提取了 Tunga penetrans。
IF 9.1 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-08-16 DOI: 10.1093/jtm/taae110
Marlene Thielecke, Andreas K Lindner

A 35-year-old traveller to West Africa returned from his trip with a sand flea embedded in his foot. The pea-sized sand flea was extracted entirely by a non-medical person, allowing an exceptional visualisation. Tungiasis, the sand flea disease, occurs sporadically in travellers. This is the second case reported from Guinea-Bissau.

一位 35 岁的西非旅行者在旅行归来时发现脚上嵌有一只沙蚤。这只豌豆大小的沙蚤完全是由一个非医务人员提取出来的,让人眼前一亮。沙蚤病(Tungiasis)在旅行者中时有发生。这是几内亚比绍报告的第二个病例。
{"title":"Entirely extracted Tunga penetrans in a traveller to Guinea-Bissau.","authors":"Marlene Thielecke, Andreas K Lindner","doi":"10.1093/jtm/taae110","DOIUrl":"https://doi.org/10.1093/jtm/taae110","url":null,"abstract":"<p><p>A 35-year-old traveller to West Africa returned from his trip with a sand flea embedded in his foot. The pea-sized sand flea was extracted entirely by a non-medical person, allowing an exceptional visualisation. Tungiasis, the sand flea disease, occurs sporadically in travellers. This is the second case reported from Guinea-Bissau.</p>","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2024-08-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141992313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Schistosomiasis in Migrants: Bridging the Gap in Italy's Treatment Guidelines and Access. 移民血吸虫病:缩小意大利在治疗指南和获取方面的差距。
IF 9.1 2区 医学 Q1 INFECTIOUS DISEASES Pub Date : 2024-08-10 DOI: 10.1093/jtm/taae107
Agnese Comelli, Andrea Angheben, Marco Albonico, Guido Calleri, Lorenzo Zammarchi, Christian Napoli, Rosalia Marrone

Schistosomiasis is a widespread disease that can cause serious health issues if not diagnosed and treated promptly. Fortunately, there is an effective and safe treatment available: praziquantel. In countries with a high influx of migrants from schistosomiasis-endemic regions, it is crucial to ensure the availability of praziquantel. This discussion will address the barriers and the need for praziquantel in Italy.

血吸虫病是一种广泛传播的疾病,如果不及时诊断和治疗,会导致严重的健康问题。幸运的是,目前有一种有效而安全的治疗方法:吡喹酮。在血吸虫病流行地区移民大量涌入的国家,确保吡喹酮的供应至关重要。本次讨论将探讨在意大利使用吡喹酮的障碍和需求。
{"title":"Schistosomiasis in Migrants: Bridging the Gap in Italy's Treatment Guidelines and Access.","authors":"Agnese Comelli, Andrea Angheben, Marco Albonico, Guido Calleri, Lorenzo Zammarchi, Christian Napoli, Rosalia Marrone","doi":"10.1093/jtm/taae107","DOIUrl":"https://doi.org/10.1093/jtm/taae107","url":null,"abstract":"<p><p>Schistosomiasis is a widespread disease that can cause serious health issues if not diagnosed and treated promptly. Fortunately, there is an effective and safe treatment available: praziquantel. In countries with a high influx of migrants from schistosomiasis-endemic regions, it is crucial to ensure the availability of praziquantel. This discussion will address the barriers and the need for praziquantel in Italy.</p>","PeriodicalId":17407,"journal":{"name":"Journal of travel medicine","volume":" ","pages":""},"PeriodicalIF":9.1,"publicationDate":"2024-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141913097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of travel medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1